Cargando…

Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study

Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measure...

Descripción completa

Detalles Bibliográficos
Autores principales: Özdirik, Burcin, Stueven, Anna K., Mohr, Raphael, Geisler, Lukas, Wree, Alexander, Knorr, Jana, Demir, Münevver, Vucur, Mihael, Loosen, Sven H., Benz, Fabian, Reiss, Markus, Wiedenmann, Bertram, Tacke, Frank, Jann, Henning, Hellberg, Teresa, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565987/
https://www.ncbi.nlm.nih.gov/pubmed/32899973
http://dx.doi.org/10.3390/jcm9092881
_version_ 1783596054222995456
author Özdirik, Burcin
Stueven, Anna K.
Mohr, Raphael
Geisler, Lukas
Wree, Alexander
Knorr, Jana
Demir, Münevver
Vucur, Mihael
Loosen, Sven H.
Benz, Fabian
Reiss, Markus
Wiedenmann, Bertram
Tacke, Frank
Jann, Henning
Hellberg, Teresa
Roderburg, Christoph
author_facet Özdirik, Burcin
Stueven, Anna K.
Mohr, Raphael
Geisler, Lukas
Wree, Alexander
Knorr, Jana
Demir, Münevver
Vucur, Mihael
Loosen, Sven H.
Benz, Fabian
Reiss, Markus
Wiedenmann, Bertram
Tacke, Frank
Jann, Henning
Hellberg, Teresa
Roderburg, Christoph
author_sort Özdirik, Burcin
collection PubMed
description Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. Results: In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Conclusion: Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients’ outcome.
format Online
Article
Text
id pubmed-7565987
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75659872020-10-26 Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study Özdirik, Burcin Stueven, Anna K. Mohr, Raphael Geisler, Lukas Wree, Alexander Knorr, Jana Demir, Münevver Vucur, Mihael Loosen, Sven H. Benz, Fabian Reiss, Markus Wiedenmann, Bertram Tacke, Frank Jann, Henning Hellberg, Teresa Roderburg, Christoph J Clin Med Article Background and aims: Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. Methods: We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. Results: In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Conclusion: Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients’ outcome. MDPI 2020-09-06 /pmc/articles/PMC7565987/ /pubmed/32899973 http://dx.doi.org/10.3390/jcm9092881 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Özdirik, Burcin
Stueven, Anna K.
Mohr, Raphael
Geisler, Lukas
Wree, Alexander
Knorr, Jana
Demir, Münevver
Vucur, Mihael
Loosen, Sven H.
Benz, Fabian
Reiss, Markus
Wiedenmann, Bertram
Tacke, Frank
Jann, Henning
Hellberg, Teresa
Roderburg, Christoph
Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title_full Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title_fullStr Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title_full_unstemmed Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title_short Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors—Results from an Exploratory Study
title_sort analysis of mir-29 serum levels in patients with neuroendocrine tumors—results from an exploratory study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565987/
https://www.ncbi.nlm.nih.gov/pubmed/32899973
http://dx.doi.org/10.3390/jcm9092881
work_keys_str_mv AT ozdirikburcin analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT stuevenannak analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT mohrraphael analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT geislerlukas analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT wreealexander analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT knorrjana analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT demirmunevver analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT vucurmihael analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT loosensvenh analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT benzfabian analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT reissmarkus analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT wiedenmannbertram analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT tackefrank analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT jannhenning analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT hellbergteresa analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy
AT roderburgchristoph analysisofmir29serumlevelsinpatientswithneuroendocrinetumorsresultsfromanexploratorystudy